FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCEN PERSONNEL PATENT AND TRADEMARK OFFICE PERSONNEL PER				ATTY DOCKET NO. 01997.033600.4	APPLIC 09/71	APPLICATION NO. 09/714,792		
LIS	T OF REF	IT AND TRADEMARK ERENCES CITED BY several sheets if nece	APPLICANT(S)	APPLICANT Mary Collins et al.				
			SEP 1 3 2004	FILING DATE November 16, 2000		GROUP 1647		
			TO TO LOCAL MAN	U.S. PATENT DOCUMENTS				
'EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS	S SUBCLASS	FILING DATE	
	-							
·	-			•				
•	 							
	 							
	· · · · · ·	 		FOREIGN PATENT DOCUMENTS				
·		DOCUMENT NUMBER	DATE	COUNTRY	CLAS	S SUBCLASS	TRANSLATION YES/NO/ OR ABSTRAC	
	ļ			· .				
	<u> </u>			· · · · · · · · · · · · · · · · · · ·				
	L	<u> </u>	L				<u> </u>	
FH		OTHER DOCUMENT(S) (Including Author, Title, Date, Perlinent Pages, Etc.) Husain, et al., "Interleukin-13 Receptor as a Unique Target for Anti-Glioblastoma Therapy", Int. J. Cancer, Vol. 92 (2001), pages 168-175						
FH		Barth, "hIL-13 PE38QQR NeoPharm", Current Opinion in Investigational Drugs, Vol. 2, No. 9 (2001), pages 1309-1313						
FH		Li, et al., "Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice", Protein Engineering, Vol. 15, No. 5 (2002), pages 419-427						
FH		Husain, et al., "Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside", <i>Journal of Neuro-Oncology</i> , Vol. 65 (2003), pages 37-48						
FH		Mintz, et al., expressing o	"Molecular targ	eting with recombinant cytotoxin of Neuro-Oncology, Vol. 64 (200	s of interle 3), pages 1	ukin-13 rece 17-123	ptor α2-	
EXAMINER	70	x 1	ma	DATE CONSIDERED \\	30 00	J		

Sheet_1_ of _ 1_

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.